Common Stock, $0.001 par value per share
- Symbol
- ZNTL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Zentalis Pharmaceuticals, Inc.
ZNTLNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 16, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).…
Company context
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
Current securities
Registered securities in this filing
ZENTALIS PHARMACEUTICALS, INC. · 8-K · Filed 2026-06-18
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 16, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 49,453,766 shares of common stock were present online or represented by proxy at the meeting, representing approximately 69.47% of the Company’s outstanding common stock as of the April 20, 2026 record date. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2026, as supplemented on May 27, 2026.